News By Tag
News By Location
TGA Sciences Announces Collaboration with New Immunoassay Platform Company
TGA Sciences, Inc. has collaborated with the makers of CyPlex LS, a new immunoassay platform, to make sure it addresses the needs of the pre-clinical and translational research marketplace.
Michael Settles, President and Founder of TGA Sciences, Inc. said, “We are very excited that this collaboration will not only assist CyVek, Inc. in optimizing and co-marketing this new technology, but also because of the abilities it will offer our growing number of clients. We see a large opportunity in this collaboration offering additional services that are applicable to both R&D efforts and further clinical studies. The CyPlex LS will add to our current offerings by allowing us to meet our client’s requests for flexibility and quick turn-around times when submitting samples for particular analysis.”
Bill Dubiel, CyVek’s Chief Commercial Officer, said, “We are excited to establish an early relationship with a high quality CRO. TGA Sciences, Inc. is a FDA registered and inspected cGMP/ GLP analytical laboratory and has partnered with us to ensure our software meets 21 CFR Part 11 compliance while we provide them the ability to provide their clients with custom developed assays on our cartridges.”
About TGA: TGA Sciences, Inc. is an FDA / EMA inspected contract research laboratory providing the Pharmaceutical, Biotechnology and Research communities a comprehensive range of laboratory services in support of research and clinical studies. For more information about TGA Sciences, Inc., please call 781-393-6910 or visit us on the web at: www.tgasciences.com.
About CyVek: CyVek is a privately funded biotechnology company dedicated to the advancement of healthcare by empowering researchers and clinicians with a disruptive technology, CyPlexTM, for performing multi-analyte immunoassays. For more information about CyVek, please call 203-679-0395 or visit us on the web at: www.cyplexsystems.com.